Kairos Pharma, Ltd. (KAPA) News
Follow Kairos Pharma, Ltd. (KAPA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
KAPA - Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
KAPA - Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
NEWS | Sep 23, 2026, 12:08 PM UTC
L
Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that Neil Bhowmick, President and Chief Scientific Officer, will both present
NEWS | Sep 23, 2026, 12:00 PM UTC
L
KAPA: ENV105 targets CD105 to reverse cancer drug resistance, with pivotal trial data expected by 2027
CD105 was highlighted as a central driver of drug resistance in cancer, with ENV105 showing promise in reversing resistance and improving outcomes in prostate and lung cancer trials. Strategic collaborations, robust fund
NEWS | Sep 14, 2026, 09:26 PM UTC
L
KAPA: ENV105 shows promise in overcoming cancer drug resistance, with pivotal trial data expected by 2026
ENV105, an antibody targeting CD105, is advancing in phase I/II trials for prostate and lung cancer, showing strong early efficacy and safety. Strategic collaborations, robust funding, and a multi-center academic consort
NEWS | Sep 14, 2026, 08:46 PM UTC
L
KAPA: ENV105 leads a robust pipeline targeting cancer resistance, with strong early clinical results and funding
Focused on overcoming cancer drug resistance and immune suppression, the company advances a pipeline led by ENV105, now in Phase 2 for prostate cancer and Phase 1 for lung cancer. Early clinical data show promising effic
NEWS | Sep 14, 2026, 08:08 PM UTC
L
Kairos Pharma to Present Investor Update at H.C. Wainwright Conference
Kairos Pharma issued a new investor presentation and will present an update on its clinical program at the H.C. Wainwright conference.Key Highlights:Original SEC Filing: Kairos Pharma, LTD. [ KAPA ] - 8-K - Sep. 14, 2026
REGULATION | Sep 14, 2026, 08:04 PM UTC
L
KAPA - Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
KAPA - Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 09, 2026, 12:05 PM UTC
L
Kairos Pharma CEO John Yu to present at H.C. Wainwright conference
Kairos Pharma said John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 09, 2026, 12:00 PM UTC
M
Kairos Pharma (KAPA) announces 1-for-7 reverse stock split
Kairos Pharma announces a 1-for-7 reverse stock split for its KAPA shares, according to the company release provided by TradeXchange Newsdesk.
EQUITY | Aug 21, 2026, 08:35 PM UTC